期刊
ARCHIVES OF NEUROLOGY
卷 62, 期 2, 页码 258-264出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archneur.62.2.258
关键词
-
资金
- NINDS NIH HHS [R01 NS40993, K24 NS44250] Funding Source: Medline
Background: Rituximab, an anti-CD20 monoclonal antibody that depletes CD20(+) B cells, has demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be translated to neurological diseases of the central nervous system with possible autoimmune B-cell involvement remains unknown. Objective: To determine the effect of rituximab on cerebrospinal fluid B cells in patients with multiple sclerosis. Design: Four patients with primary progressive multiple sclerosis were treated with rituximab. Cerebrospinal fluid and peripheral blood B-cell subsets were identified by flow cytometry from each patient before and after rituximab treatment. Results: The B cells in cerebrospinal fluid were not as effectively depleted as their peripheral blood counterparts. Rituximab treatment temporarily suppressed the activation state of B cells in cerebrospinal fluid. The residual B cells underwent expansion after rituximab treatment. Conclusion: The effect(s) of rituximab on the cerebrospinal fluid B-cell compartment is limited in comparison with the effect(s) on the B cells in the periphery, but this finding will need to be confirmed in a larger group of MS patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据